Sprintful vs Theraplo: Comparison of Top Scheduling Tools
Which one is a better scheduling solution for you? Sprintful or maybe Theraplo?
Compare Sprintful and Theraplo Websites


Watch and Compare Sprintful and Theraplo Promo Videos on YouTube.
Main Points to Consider for Sprintful vs Theraplo
Sprintful has a rating of 3.5, while Theraplo does not yet have a rating on platforms like Capterra, Trustpilot, or GetApp. The Sprintful Standard plan costs $19 monthly, per user, compared to Theraplo's $14.99 monthly, per user. Compare Sprintful and Theraplo features based on collected data and real user reviews that highlight their possibilities, issues, customer service, and value for money.
Key consideration for Sprintful: Sprintful is user-friendly and highly customizable with robust integrations, but it's expensive, has poor design, and lacks responsive customer support.
Key consideration for Theraplo: Theraplo focuses on medical and therapeutic practices, offering industry-specific features (therapeutic contracts, office rental billing, commission-based settlements). It supports calendar and client-panel customization, Google Meet via Google Calendar, API access, a Help Center, and a dedicated phone support line. Theraplo does not impose visit, SMS, or email limits, as it integrates directly with clients' own systems.
User Reviews
What Are Users Saying About Sprintful?
[...] It is very user-friendly, allows for comprehensive and easy integrations, and I have had zero issues.
[...] Help clients to schedule a meeting, book a seat in one of the upcoming sessions and book a service with us
[...] Very flexible, slick experience, and can be fully customized. Has all the needed integrations and can handle complex scenarios.
[...] They charge large amount of money and this is to much expensive
[...] Bad design, expensive tool.
[...] Can't reach the support, it's terrbile when you have a problem and they don't answer.
What Are Users Saying About Theraplo?
No public reviews available for Theraplo on Capterra, G2, or Trustpilot at this time.